{"entity":{"id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","aka":[],"tldr":"A phase 2 trial of pembrolizumab and INBRX-106 in triple-negative breast cancer, run by Providence Health & Services, now recruiting.","summary":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients is a phase 2, interventional study registered as NCT06353997 by Providence Health & Services, with a registry enrolment figure of 12 participants, started 2024-09-05 and due to reach its primary completion in 2027-06. Interventions recorded: Pembrolizumab; INBRX-106. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients must have histologically confirmed TNBC (ER/PR ≤ 10% allowed, HER2- as defined by ASCO guidelines)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06353997","url":"https://clinicaltrials.gov/study/NCT06353997"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","inbrx-106"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06353997","phase":"2","setting":"A Phase II, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as an Induction Immunotherapy for Stage II/III TNBC Patients","sponsor":"Providence Health & Services","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06353997/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}